Save
Email
Print
ShareFeb. 9, 2012 — An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia in individuals with type 1 diabetes, according to a study published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc.
In the study, Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver, and colleagues from the Barbara Davis Center for Childhood Diabetes (Aurora, CO), Rainier Clinical Research Center (Renten, WA), AMCR Institute, Inc. (Escondido, CA), Stanford University Medical Center (CA), Mills-Peninsula Health Services (San Mateo, CA), and Medtronic Inc. (Northridge, CA) used a regimen of fasting and exercise to induce hypoglycemia in a group of subjects with type 1 diabetes who use insulin pump delivery devices along with continuous glucose monitoring.
They compared the severity and duration of hypoglycemia and the risk of rebound hyperglycemia when the automated "low glucose suspend" feature of the pump was turned on or off. They report their findings in the article "Reduction in Duration of Hypoglycemia by Automatic Suspension of Insulin Delivery: The In-Clinic ASPIRE Study."
"This is the first randomized cross-over trial with an attempt to develop an artificial pancreas," says Dr. Garg.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Mary Ann Liebert, Inc..
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Satish Garg, Ronald L. Brazg, Timothy S. Bailey, Bruce A. Buckingham, Robert H. Slover, David C. Klonoff, John Shin, John B. Welsh, Francine R. Kaufman. Reduction in Duration of Hypoglycemia by Automatic Suspension of Insulin Delivery: The In-Clinic ASPIRE Study. Diabetes Technology & Therapeutics, 2012; 120208122710007 DOI: 10.1089/dia.2011.0292
Note: If no author is given, the source is cited instead.
more 
